SANJEEV JAIN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- PATCHOGUE, NY
- NPI
- 1851497341
- Received
- $971,487 in 93 records, 2019 to 2025
- As principal investigator
- $213,400 of research payments to others in 45 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 30 | $440,074 |
| 2024 | General payment | 25 | $439,342 |
| 2023 | General payment | 8 | $8,495 |
| 2022 | General payment | 3 | $243 |
| 2021 | General payment | 9 | $27,606 |
| 2020 | General payment | 11 | $12,411 |
| 2019 | General payment | 7 | $43,313 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 40 | $795,200 | 2024–2025 |
| Incyte Corporation | 17 | $92,350 | 2023–2025 |
| Merck Sharp & Dohme LLC | 20 | $82,115 | 2019–2022 |
| Innate Pharma, Inc | 1 | $1,200 | 2020 |
| Novocure Inc. | 1 | $148 | 2025 |
| Janssen Biotech, Inc. | 2 | $127 | 2022 |
| Lilly USA, LLC | 1 | $120 | 2024 |
| Genentech USA, Inc. | 3 | $69 | 2019–2024 |
| Kite Pharma, Inc. | 3 | $61 | 2020–2021 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 | 2025 |
| SERVIER PHARMACEUTICALS LLC | 1 | $22 | 2023 |
| CTI BioPharma Corp. | 1 | $22 | 2023 |
| Gilead Sciences, Inc. | 1 | $11 | 2021 |
| Novartis Pharmaceuticals Corporation | 1 | $11 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 76 | $969,550 |
| Honoraria | 1 | $1,200 |
| Food and Beverage | 14 | $625 |
| Education | 2 | $111 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-04 | PFIZER INC. | $1,200 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-12-04 | PFIZER INC. | $600 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-11-06 | PFIZER INC. | $6,900 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-10-29 | PFIZER INC. | $48,000 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-10-29 | PFIZER INC. | $3,600 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-10-22 | Novocure Inc. | $148 | Food and Beverage | Cash or cash equivalent | Optune Lua (NovoTTF-200T) Device, Oncology | 2025 | |
| 2025-10-09 | PFIZER INC. | $6,900 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-10-03 | PFIZER INC. | $8,400 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-10-01 | Regeneron Healthcare Solutions, Inc. | $25 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-11 | Incyte Corporation | $9,800 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-04 | PFIZER INC. | $44,400 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-09-04 | Incyte Corporation | $7,400 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-04 | Incyte Corporation | $7,000 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-04 | PFIZER INC. | $1,500 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-08-26 | PFIZER INC. | $1,800 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-07-31 | Incyte Corporation | $7,300 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-10 | PFIZER INC. | $48,500 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-07-10 | PFIZER INC. | $4,200 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-06-05 | PFIZER INC. | $2,100 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-05-22 | PFIZER INC. | $48,300 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-05-22 | PFIZER INC. | $3,900 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-04-08 | PFIZER INC. | $1,800 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-04-08 | PFIZER INC. | $400 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-04-03 | Incyte Corporation | $35,100 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-03-04 | PFIZER INC. | $29,100 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-02-06 | PFIZER INC. | $33,000 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-01-23 | Incyte Corporation | $8,400 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-01-21 | PFIZER INC. | $66,900 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-01-17 | PFIZER INC. | $600 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-01-07 | Incyte Corporation | $2,800 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2024-12-17 | Genentech USA, Inc. | $22 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2024 | |
| 2024-12-03 | Incyte Corporation | $5,400 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-12-03 | Incyte Corporation | $350 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-11-26 | PFIZER INC. | $46,900 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-10-18 | PFIZER INC. | $68,100 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-10-08 | Incyte Corporation | $175 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-09-20 | PFIZER INC. | $1,900 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-09-05 | Incyte Corporation | $175 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-08-01 | PFIZER INC. | $16,200 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-08-01 | PFIZER INC. | $1,800 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-06-13 | PFIZER INC. | $39,900 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-05-29 | PFIZER INC. | $57,300 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-05-09 | PFIZER INC. | $600 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-04-23 | PFIZER INC. | $48,000 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-04-12 | PFIZER INC. | $33,300 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-03-05 | Lilly USA, LLC | $120 | Food and Beverage | Cash or cash equivalent | JAYPIRCA Drug, Oncology | 2024 | |
| 2024-02-29 | PFIZER INC. | $19,300 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-01-16 | PFIZER INC. | $40,200 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-01-16 | PFIZER INC. | $25,900 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-01-16 | PFIZER INC. | $24,600 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-01-16 | PFIZER INC. | $3,800 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-01-16 | PFIZER INC. | $3,300 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-01-16 | PFIZER INC. | $900 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-01-16 | PFIZER INC. | $800 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-01-16 | PFIZER INC. | $300 | Consulting Fee | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2023-08-10 | Incyte Corporation | $1,400 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-10 | Incyte Corporation | $700 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-10 | Incyte Corporation | $262 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-10 | Incyte Corporation | $87 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-08 | Incyte Corporation | $5,200 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-08 | Incyte Corporation | $800 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-05 | SERVIER PHARMACEUTICALS LLC | $22 | Food and Beverage | In-kind items and services | Tibsovo Drug, Oncology | 2023 | |
| 2023-02-16 | CTI BioPharma Corp. | $22 | Food and Beverage | In-kind items and services | Vonjo Drug, Hematology | 2023 | |
| 2022-11-03 | Merck Sharp & Dohme LLC | $115 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-04-04 | Janssen Biotech, Inc. | $99 | Education | In-kind items and services | ERLEADA Drug, Oncology | 2022 | |
| 2022-01-11 | Janssen Biotech, Inc. | $27 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2022 | |
| 2021-12-08 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2021 | |
| 2021-10-18 | Merck Sharp & Dohme LLC | $5,175 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2021 | |
| 2021-08-13 | Merck Sharp & Dohme LLC | $2,970 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2021 | |
| 2021-08-02 | Merck Sharp & Dohme LLC | $75 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2021 | |
| 2021-06-22 | Kite Pharma, Inc. | $19 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-06-01 | Gilead Sciences, Inc. | $11 | Education | In-kind items and services | 2021 | ||
| 2021-05-13 | Merck Sharp & Dohme LLC | $16,245 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2021 | |
| 2021-04-12 | Merck Sharp & Dohme LLC | $3,060 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2021 | |
| 2021-04-09 | Kite Pharma, Inc. | $26 | Food and Beverage | In-kind items and services | 2021 | ||
| 2020-12-03 | Merck Sharp & Dohme LLC | $525 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-11-12 | Merck Sharp & Dohme LLC | $2,500 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-11-12 | Merck Sharp & Dohme LLC | $1,200 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-11-04 | Novartis Pharmaceuticals Corporation | $11 | Food and Beverage | In-kind items and services | PIQRAY Drug, ONCOLOGY | 2020 | |
| 2020-08-17 | Merck Sharp & Dohme LLC | $1,000 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-07-29 | Kite Pharma, Inc. | $15 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-07-09 | Merck Sharp & Dohme LLC | $3,400 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-07-09 | Merck Sharp & Dohme LLC | $1,600 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-07-08 | Innate Pharma, Inc | $1,200 | Honoraria | Cash or cash equivalent | Lumoxiti Drug, Oncology | 2020 | |
| 2020-07-08 | Merck Sharp & Dohme LLC | $150 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-03-19 | Merck Sharp & Dohme LLC | $810 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2019-11-14 | Merck Sharp & Dohme LLC | $270 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-08-14 | Merck Sharp & Dohme LLC | $945 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-08-01 | Merck Sharp & Dohme LLC | $3,240 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-07-25 | Merck Sharp & Dohme LLC | $31,905 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-05-23 | Merck Sharp & Dohme LLC | $990 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-04-18 | Merck Sharp & Dohme LLC | $5,940 | Consulting Fee | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-02-23 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Xolair Biological, Immunology | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-05-13 | AstraZeneca UK Limited | RAD MD LLC | $440 | a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus t | 2025 |
| 2025-01-14 | AstraZeneca UK Limited | RAD MD LLC | $10,285 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2025 |
| 2024-12-31 | AstraZeneca UK Limited | RAD MD LLC | $1,969 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2024 |
| 2024-06-13 | Incyte Corporation | RADMD LLC | $700 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2024 |
| 2024-06-13 | Incyte Corporation | RADMD LLC | $175 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2024 |
| 2024-05-29 | Incyte Corporation | RADMD LLC | $175 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2024 |
| 2024-02-13 | AstraZeneca UK Limited | RAD MD LLC | $34,485 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2024 |
| 2023-12-31 | AstraZeneca UK Limited | RAD MD LLC | $191 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2023 |
| 2023-12-14 | MorphoSys AG | RADMD LLC | $1,400 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2023 |
| 2023-12-14 | MorphoSys AG | RADMD LLC | $175 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2023 |
| 2023-05-09 | MorphoSys AG | RADMD LLC | $175 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2023 |
| 2023-05-09 | MorphoSys AG | RADMD LLC | $350 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2023 |
| 2023-01-10 | AstraZeneca UK Limited | RAD MD LLC | $3,355 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2023 |
| 2022-12-31 | Acerta Pharma LLC | RAD MD LLC | $334 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2022 |
| 2022-12-31 | Acerta Pharma LLC | RADMD LLC | $459 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2022 |
| 2022-12-08 | MorphoSys AG | RADMD LLC | $700 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2022 |
| 2022-07-14 | Acerta Pharma LLC | RAD MD LLC | $7,700 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2022 |
| 2022-04-13 | MorphoSys AG | RADMD LLC | $175 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2022 |
| 2022-03-31 | Acerta Pharma LLC | RADMD LLC | $10,560 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2022 |
| 2022-02-03 | MorphoSys AG | RADMD LLC | $350 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2022 |
| 2021-12-31 | AstraZeneca UK Limited | RADMD LLC | $279 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-12-31 | Acerta Pharma LLC | RADMD LLC | $2,098 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-12-31 | Acerta Pharma LLC | RAD MD LLC | $1,108 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-09-12 | MorphoSys AG | RADMD LLC | $700 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2021 |
| 2021-08-25 | MorphoSys AG | RADMD LLC | $1,400 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2021 |
| 2021-06-14 | AstraZeneca UK Limited | RADMD LLC | $4,895 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-06-10 | Takeda Pharmaceuticals U.S.A., Inc. | RADMD LLC | $350 | A PHASE 4, OPEN-LABEL, SINGLE-ARM STUDY OF BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLAST | 2021 |
| 2021-04-16 | MorphoSys AG | RADMD LLC | $700 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2021 |
| 2021-04-12 | Acerta Pharma LLC | RAD MD LLC | $19,415 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-04-08 | BeiGene USA, Inc. | RAD MD LLC | $210 | A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kin | 2021 |
| 2021-03-18 | MorphoSys AG | RADMD LLC | $350 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2021 |
| 2021-02-25 | BeiGene (Suzhou) Co., Ltd. | RAD MD LLC | $4,340 | A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kin | 2021 |
| 2021-02-25 | BeiGene (Suzhou) Co., Ltd. | RAD MD LLC | $700 | A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kin | 2021 |
| 2021-02-11 | MorphoSys AG | RADMD LLC | $350 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2021 |
| 2021-02-11 | Acerta Pharma LLC | RADMD LLC | $36,740 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2021 |
| 2021-01-15 | MorphoSys AG | RADMD LLC | $1,400 | A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patien | 2021 |
| 2021-01-07 | EMD Serono, Inc. | RADMD LLC | $6,000 | A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresect | 2021 |
| 2020-12-31 | Acerta Pharma LLC | RADMD LLC | $45 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2020 |
| 2020-11-12 | Acerta Pharma LLC | RADMD LLC | $800 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2020 |
| 2019-12-31 | Acerta Pharma LLC | RADMD LLC | $12 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2019 |
| 2019-08-14 | Verastem, Inc. | RAD MD LLC | $2,700 | A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) | 2019 |
| 2019-04-10 | ABBVIE INC. | RADIATION MD LLC | $12,530 | M12-175 | 2019 |
| 2019-04-04 | ABBVIE INC. | RADIATION MD LLC | $1,610 | M12-175 | 2019 |
| 2019-03-07 | Acerta Pharma LLC | RADMD LLC | $220 | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2019 |
| 2019-01-10 | Acerta Pharma LLC | RADMD LLC | $40,290 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Patchogue, NY, county Suffolk County, NY, state New York; placed by its city name.
| Measure | Place (city or town) Patchogue, NY | County Suffolk County, NY | State New York |
|---|---|---|---|
| Population B01003 | 12,396 | 1,530,146 | 19,852,366 |
| Population, 2020 census P1 | 12,408 | 1,525,920 | 20,201,249 |
| Median age B01002 | 39.5 | 41.7 | 39.8 |
| Under 18 B01001 | 15.9% | 20.8% | 20.5% |
| 65 and over B01001 | 14.0% | 17.9% | 17.9% |
| Households B11001 | 5,325 | 512,565 | 7,722,646 |
| Foreign born B05002 | 13.4% | 16.8% | 22.8% |
| Median household income B19013 | $107,306 | $130,686 | $85,974 |
| Median family income B19113 | $122,085 | $150,525 | $106,873 |
| Per capita income B19301 | $52,745 | $57,164 | $50,712 |
| Poverty rate B17001 | 10.6% | 6.4% | 14.0% |
| Unemployment rate B23025 | 3.5% | 4.7% | 6.4% |
| Civilian labor force B23025 | 7,850 | 820,542 | 10,171,766 |
| Mean commute (minutes) B08013 | 32.4 | 31.1 | 32.6 |
| Bachelor's degree or higher B15003 | 35.1% | 40.2% | 40.2% |
| Housing units B25001 | 5,797 | 580,772 | 8,585,241 |
| Owner-occupied B25003 | 55.2% | 82.2% | 54.3% |
| Renters B25003 | 44.8% | 17.8% | 45.7% |
| Median home value B25077 | $477,600 | $578,400 | $423,800 |
| Median gross rent B25064 | $2,263 | $2,255 | $1,621 |
| White, not Hispanic B03002 | 62.9% | 62.0% | 52.8% |
| Black B03002 | 6.5% | 6.9% | 13.4% |
| Hispanic or Latino B03002 | 22.3% | 22.8% | 19.8% |
| Asian B03002 | 4.1% | 4.4% | 9.0% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Patchogue, NY.
Comments